A Phase 1 Dose-Escalation Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-Refractory Non-Muscle-Invasive Bladder Cancer
Latest Information Update: 09 Jul 2024
Price :
$35 *
At a glance
- Drugs Pembrolizumab (Primary) ; BCG
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions; First in man
- 26 Jun 2024 Status changed from discontinued to completed.
- 28 Nov 2022 Status has been changed to discontinued, as per Results published in the European Urology
- 28 Nov 2022 Results published in the European Urology